---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/43496464.md"
description: "What I want to see goes beyond the current pain points of mRNA therapeutics; it needs to be more direct. Do you feel that mRNA applications are currently concentrated on vaccine development? This business logic is tied to US health insurance and genomic sequencing, which is one key point.Another point: how can we expand mRNA beyond vaccines, genetic diseases, and rare diseases? What's missing right now? Who has the capability?Are there payment pathways outside the current commercial insurance system?"
datetime: "2026-08-19T16:44:07.000Z"
locales:
  - [en](https://longbridge.com/en/topics/43496464.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/43496464.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/43496464.md)
author: "[輸棟樓的韭菜](https://longbridge.com/en/profiles/10647684.md)"
generator: "portal-rs"
---

# What I want to see goes beyond the current pain po…


### Related Stocks

- [TEM.US](https://longbridge.com/en/quote/TEM.US.md)
- [02228.HK](https://longbridge.com/en/quote/02228.HK.md)
- [TXG.US](https://longbridge.com/en/quote/TXG.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**